BAO PHARMA-B's stock price surged 5.56% during intraday trading on Thursday, reflecting strong positive investor sentiment.

The significant movement follows the company's announcement that its share repurchase authorization was formally approved at an extraordinary general meeting. The approval empowers the board to conduct buybacks of up to 10% of the company's issued H shares based on market conditions. Furthermore, Board Chairman Dr. Liu Yanjun has announced plans to personally increase his holdings through open market transactions within the next three months. These actions are seen as a strong signal of management's confidence in the company's long-term investment value.

The broader Biotechnology sector also demonstrated strength during the session, providing additional tailwinds for the stock's performance.